Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

20%

1 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed trials have results

Key Signals

Enrollment Performance

Analytics

N/A
3(75.0%)
Phase 4
1(25.0%)
4Total
N/A(3)
Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT06434649Not ApplicableActive Not Recruiting

Posterior Extra-fascial RARP in Intermediate or High Risk Prostate Cancer

Role: collaborator

NCT03207100Not ApplicableCompleted

Analgesia-first Minimal Sedation for Spontaneous Intracerebral Hemorrhage Early Antihypertensive Treatment

Role: collaborator

NCT05529212Unknown

Cardiac Surgery and Postoperative Organ Dysfunction

Role: collaborator

NCT03536611Phase 4Unknown

Dabigatran Versus Warfarin With NVAF Who Undergo PCI

Role: collaborator

NCT02352012Not ApplicableUnknown

Interventional Treatment of Refractory Pneumothorax by Bronchoscope

Role: collaborator

All 5 trials loaded